The clinical efficacy and safety of Ginkgo biloba in vertigo patients: A meta-analysis

IF 1.7 Q2 Medicine Advances in integrative medicine Pub Date : 2023-12-01 DOI:10.1016/j.aimed.2023.10.001

Xiang Gao, Yan Cheng, Fangyuan Liu, Xiaozhen Han, Chuanliang Liu

{"title":"The clinical efficacy and safety of Ginkgo biloba in vertigo patients: A meta-analysis","authors":"Xiang Gao, Yan Cheng, Fangyuan Liu, Xiaozhen Han, Chuanliang Liu","doi":"10.1016/j.aimed.2023.10.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>We detected the clinical efficacy and safety of <em>Ginkgo biloba</em> in vertigo patients through a meta-analysis method.</div></div><div><h3>Method</h3><div>PubMed, Web of Science, Embase, Cochrane, EBSCO, CBM, CNKI, and Wanfang databases were searched for randomized controlled trials. Data about the clinical efficacy and safety of vertigo patients were collected. The <em>Ginkgo biloba</em> groups were pooled to compare with the control groups and obtain the pooled odds ratios and associated 95 % confidence interval.</div></div><div><h3>Results</h3><div>We retrieved 25 randomized controlled studies enrolling 1209 patients. The addition of <em>Ginkgo biloba</em> improved vertigo in patients with vertebrobasilar artery insufficiency, cervical vertigo, and not-specific-disease vertigo but not in BPPV and Meniere’s disease. The incidence of adverse reactions such as headache, gastrointestinal discomfort, and skin rashes in the <em>Ginkgo biloba</em> group did not differ significantly from that of the control group.</div></div><div><h3>Conclusion</h3><div>The addition of <em>Ginkgo biloba</em> had better clinical efficacy in patients with vertebrobasilar artery insufficiency, cervical vertigo, and not-specific-disease vertigo but not in BPPV and Meniere’s disease, and the <em>Ginkgo biloba</em> group had no significant differences in adverse reactions compared with the control group.</div></div>","PeriodicalId":7343,"journal":{"name":"Advances in integrative medicine","volume":"10 4","pages":"Pages 158-166"},"PeriodicalIF":1.7000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in integrative medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212958823000836","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

We detected the clinical efficacy and safety of Ginkgo biloba in vertigo patients through a meta-analysis method.

Method

PubMed, Web of Science, Embase, Cochrane, EBSCO, CBM, CNKI, and Wanfang databases were searched for randomized controlled trials. Data about the clinical efficacy and safety of vertigo patients were collected. The Ginkgo biloba groups were pooled to compare with the control groups and obtain the pooled odds ratios and associated 95 % confidence interval.

Results

We retrieved 25 randomized controlled studies enrolling 1209 patients. The addition of Ginkgo biloba improved vertigo in patients with vertebrobasilar artery insufficiency, cervical vertigo, and not-specific-disease vertigo but not in BPPV and Meniere’s disease. The incidence of adverse reactions such as headache, gastrointestinal discomfort, and skin rashes in the Ginkgo biloba group did not differ significantly from that of the control group.

Conclusion

The addition of Ginkgo biloba had better clinical efficacy in patients with vertebrobasilar artery insufficiency, cervical vertigo, and not-specific-disease vertigo but not in BPPV and Meniere’s disease, and the Ginkgo biloba group had no significant differences in adverse reactions compared with the control group.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

银杏叶治疗眩晕患者的临床疗效和安全性：一项meta分析

目的通过荟萃分析方法检测银杏叶治疗眩晕患者的临床疗效和安全性。方法检索pubmed、Web of Science、Embase、Cochrane、EBSCO、CBM、CNKI、万方等随机对照试验数据库。收集眩晕患者的临床疗效和安全性数据。将银杏叶组与对照组进行合并比较，获得合并优势比和相关的95%置信区间。结果我们检索了25项随机对照研究，纳入1209例患者。银杏叶的加入改善了椎基底动脉功能不全、颈性眩晕和非特异性疾病性眩晕患者的眩晕，但对BPPV和梅尼埃病无效。银杏叶组的头痛、胃肠道不适、皮疹等不良反应发生率与对照组无显著差异。结论添加银杏叶对椎基底动脉供血不足、颈性眩晕、非特异性眩晕有较好的临床疗效，但对BPPV、梅尼埃病无明显疗效，且银杏叶组不良反应与对照组比较无显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Advances in integrative medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

3.20

自引率

11.80%

发文量

审稿时长

15 weeks

期刊介绍： Advances in Integrative Medicine (AIMED) is an international peer-reviewed, evidence-based research and review journal that is multi-disciplinary within the fields of Integrative and Complementary Medicine. The journal focuses on rigorous quantitative and qualitative research including systematic reviews, clinical trials and surveys, whilst also welcoming medical hypotheses and clinically-relevant articles and case studies disclosing practical learning tools for the consulting practitioner. By promoting research and practice excellence in the field, and cross collaboration between relevant practitioner groups and associations, the journal aims to advance the practice of IM, identify areas for future research, and improve patient health outcomes. International networking is encouraged through clinical innovation, the establishment of best practice and by providing opportunities for cooperation between organisations and communities.